CRISPR Therapeutics AG

News & Events zu CRISPR Therapeutics AG (CRSP)

$50.040

+0.801 (+1.60%)Zum Schluss

CRSP-News

CRSP-Events

10/19 16:30

Crispr Therapeutics CFO Raju Prasad Resigns, A.J. Silver to Succeed

Crispr Therapeutics announced that its CFO, Raju Prasad will be stepping down from the company to pursue external opportunities, and A.J. Silver, the company's senior VP of finance, will succeed Prasad as CFO. This transition will be effective immediately.

9/23 14:30

Anthropic Launches Life Sciences Research Group

Anthropic is introducing a new life sciences research group and laboratory, with a focus on fundamental biology research using Claude - exploring datasets of DNA to identify uncharacterized protein families, generating hypotheses at scale, and testing them through experiments in the lab. Anthropic is also sharing early results in which Claude discovered a novel enzyme system with properties reminiscent of CRISPR, with only high-level direction from its scientists. "Today, we're sharing early results from one of our first research programs, in which Claude autonomously discovered a novel enzyme system that is associated with an array of DNA repeats, a pattern reminiscent of CRISPR. Although we don't yet know its function, the system that Claude discovered has a set of characteristics that have only ever been found together in a handful of other systems, all of which are programmable and perform operations like cutting, copying, and pasting DNA. Beyond CRISPR, which has already transformed science and medicine, several other such systems are now in development as promising tools. The system that Claude found is based on a reverse transcriptase, enzymes that copy RNA into DNA. While this underlying RT, found in a jumbo phage, had been identified in previous studies, Claude appears to be the first to notice the system's defining features-an associated array of non-coding DNA sequences and an additional accessory protein of unknown function," the company said. Shares of Crispr Therapeutics (CRSP) are down more than 4% at $56.39 in afternoon trading.

8/3 17:00

CRISPR Therapeutics Q2 Revenue $10.18M Beats Expectations

Reports Q2 revenue $10.18M, consensus $7.43M. "The second quarter reflected strong execution across CRISPR Therapeutics' portfolio and platform," said Samarth Kulkarni, Chairman and Chief Executive Officer of CRISPR Therapeutics. "CASGEVY's momentum continued to build, highlighted by the FDA's approval for children as young as 2 years old, while we expanded our in vivo pipeline with the initiation of Phase 1 clinical trials for CTX340 for refractory hypertension and CTX460 for alpha-1 antitrypsin deficiency. We enter the second half of 2026 well positioned, with a number of important milestones ahead across our pipeline."

Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.

Jetzt handeln